FENC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
17.9M
+18.3%
15.1M
+9.7%
13.8M
+10.6%
12.5M
+29.1%
9.7M
Cost of Revenue
721.0K
+26.5%
570.0K
-67.7%
1.8M
+167.3%
660.0K
-31.7%
967.0K
Gross Profit
17.2M
+18.0%
14.5M
+21.0%
12.0M
+1.8%
11.8M
+35.9%
8.7M
Operating Expenses
15.4M
+5.2%
14.7M
+0.6%
14.6M
+21.5%
12.0M
+5.0%
11.4M
R&D
118.0K
+140.8%
49.0K
+145.0%
20.0K
-31.0%
29.0K
-72.9%
107.0K
SG&A
15.3M
+4.7%
14.6M
+0.4%
14.5M
+21.6%
12.0M
+5.8%
11.3M
Operating Income
1.7M
+1559.7%
-119000
+95.3%
-2554000
-1251.3%
-189000
+93.1%
-2732000
EBITDA
1.7M
+1559.7%
-119000
+95.3%
-2554000
-1251.3%
-189000
+93.1%
-2732000
Net Income
2.0M
+881.6%
201.0K
+104.2%
-4787000
-650.3%
-638000
+79.8%
-3152000
EPS (Basic)
$0.06
+500.0%
$0.01
+106.7%
$-0.15
-650.0%
$-0.02
+81.8%
$-0.11
EPS (Diluted)
$0.05
+400.0%
$0.01
+106.7%
$-0.15
-650.0%
$-0.02
+81.8%
$-0.11
Shares (Diluted)
36.4M
+2.5%
35.5M
+14.0%
31.2M
+11.8%
27.9M
+0.8%
27.7M
Fennec Pharmaceuticals (FENC) โ€” Financials